aTYR Pharma Q3 2026 Results: Net Loss of $18.3M, Loss Narrows
For the nine months ended September 30, 2026, aTyr Pharma reported a consolidated net loss of $39.4 million, an improvement from the $60.2 million loss in the prior year period. Total assets decreased to $59.8 million from $93.0 million at year-end 2025, primarily due to a reduction in available-for-sale investments used to fund operations.
- Key figure
- Net loss $18.3M